While Rybelsus is licensed for the treatment of type 2 diabetes, oral Wegovy has been specifically approved for weight management, marking the first time an oral GLP-1 has been licensed for obesity treatment in the UK
A separate reviewer has disclosed that they have served as a consultant for Applied Therapeutics, Novo Nordisk, Pfizer and Sanofi
Studies have shown that approximately half of the weight lost by GLP-1 users is not fat, but muscle
Of the few Marketplace plans that cover GLP-1 drugs approved for obesity, all require prior authorization
Please note that these are merely associations as they appear in the given model and do not represent effects that may be interpreted in any causal manner
The longer food takes to digest, the slower the gastric emptying which can exacerbate any adverse gastrointestinal effects